Positive updates from Praxis Precision, Clene Inc., and Swiss Biotech Vandria on their respective drug trials.
Aspen Neuroscience closes Series C. Who took a piece of this $115 financing round? Find out here!
This common antibiotic could reduce the risk of schizophrenia. And we finally have proof of the link between trauma and misbehavior.
How music and light help slow cognitive decline. Plus BridgeBio gets a stock bump.
Playing a clarinet while receiving brain surgery? Yep, it really happened. Plus the reason Alto Neuroscience's share price is on the rise.
How this company is leveraging AI to create new medicine to treat ALS; plus Roche receives FDA approval for test of Alzheimer's treatment
Scientists may have just reversed Alzheimer's in mice brains; and did ancient Peruvians drink psychedelic beer?
China announces major milestone for their brain-computer interface medical device program.
atai Life Sciences and Beckley Psytech seek further FDA approval after positive results from depression treatment study.
LB Pharmaceuticals IPO LB-102 icobrain icometrix charles zucker ge healthcare
Gilgamesh receives a billion dollar commitment from AbbVie, a historic moment in the relationship between big pharma and psychedelics.
Cybin is now cleared to study CYB003 on three continents, and a new study offers new insight into how Parkinson's occurs.
PharmaTher Holdings announces FDA approval for its ketamine product, KETARx™, for use in surgical pain management – a "historic" moment.
Stanford and Emory BrainGate may literally give a voice to the voiceless; Reunion Neuroscience announced positive topline results.
Clearmind is cleared to begin in-human trials of its MEAI-based oral drug designed to treat Alcohol Use Disorder.
How scientists use VR to understand infectious diseases – specifically the surprising way proximity to disease triggers our immune systems.
Tryptamine Therapeutics begins eating disorder treatment trial. And could these cancer drugs reduce the risk of alzheimer's?
Dogs that detect Parkinson's disease? It's not science fiction! Plus how music maintains cognitive functions as we age.
Could psilocybin be the secret to staying young? How this psychedelic compound might increase the lifespan of human cells and slow aging.
atai Life Sciences and Beckley Psytech successfully completed Phase IIb of their study of their new psychedelic therapy.
Who's faster at learning language: AI or a child? The answer may shock you. Plus the surprising connection between autism and heart disease.
China launches their clinical trial of a Brain Computer Interface (BCI). This wireless invasive BCI will attempt to treat tetraplegia.
NewAmsterdam Pharma's Alzheimer's drug passes another test. Plus how genetic variations make us more or less susceptible to our environment.
Computer chips in your brain are coming! Paradromics successfully demonstrates BCI technology in the human brain, moving one step closer to clinical trials.
Gilgamesh beats Johnson & Johnson! At least that's what the Phase2a results from its treatment for Major Depressive Disorder suggests.
Could we diagnose Parkinson's disease before symptoms appear? The secret is in our eyes! No, seriously...
Our diet's shocking link to Parkinson's disease. Plus new insights into the fight to prevent Alzheimer's disease.
Could Ketamine treat fibromyalgia? Silo Pharma believes they've found a safe and long-acting alternative to addictive opioids.
This is a big one! A company in our portfolio just raised $13.5 million. Read about their remarkable work here.
FDA approves brain-computer interface from Precision Neuroscience, which will now be authorized for commercial use.
Think your brain and body age separately? Think again! New studies reveal just how closely brain health is tied to physical health.
A new brain chip could restore speech to people with paralysis. Plus "laughing gas" may have an unexpected health function.
One of our portfolio companies scores a massive deal. Plus want to reduce your anxiety? The key may be targeting specific neurons.
Could this drink prevent alzheimer's? And Clearmind Medicine initiates new clinical trial for its Alcohol Use Disorder treatment.
A big update from Immunis, the latest investment in our portfolio, highlights a week full of exciting developments in the our industry.
Hawaii says aloha to special fund designed to support clinical research into psychedelic-assisted treatment using psilocybin and MDMA.
Have scientists finally discovered the source of spoken language? Plus Colorado issues first psilocybin licenses to businesses.
Major updates from Tripp, Inc., Enthea and Fluence – read what our portfolio companies accomplished 2024, and look ahead towards 2025.
Virginia on the verge of allowing vets to use psychedelics; GH Research shows huge promise with new drug for treatment-resistant depression
"Dry January" is almost over, but atai Life Sciences might keep people sober thanks to its experimental and promising AUD treatment.
Cellares raises $257 million for "Smart Factory," their commercial-grade cell therapy manufacturing system.
Reunion secures Breakthrough Therapy Designation from the FDA, paving the way for its postpartum depression treatment.
Humans can now move things with their minds. Wait, and they can fly drones too? Read about the latest brain-computer interface advancement.
Cybin, Inc. launches its first strategic partnership program; Johnson & Johnson makes a major acquisition.
Silo Pharma awarded patent for PTSD treatment; New York seeks to remove a host of substances from its Schedule 1 list.
The North Star State points the way towards psilocybin decriminalization, thanks to broad bipartisan support.
Zebrafish love ketamine, MindMed begins its Phase 3 Voyage, and the DEA calls for increased DMT production.
Can people change? New research into our emotions says yes, and reveals the genetic mechanism that allows change to happen.
This hasn't happened in the psychedelics industry for 50 years... until now. Read all about this game-changer, and more!
Enveric Biosciences takes major step towards submitting new drug application to the FDA; how AI could improve neuroscience studies.
Cybin's data demonstrates remarkable response rate; Tryptamine advances trial; Georgia progresses bi-partisan psychedelics proposal.
Cybin begins critical phase in the development of Paradigm, their treatment for major depressive disorder; Trace secures Series A funding.
Precision Neuroscience raises $93M; non-invasive brain interface tech. New BNC2 neuron discovery targets appetite regulation. PharmAla to supply MDMA for Yale PTSD trial.
Gilgamesh could be on its way to becoming a billion dollar company; we've got the details on this new deal involving our portfolio company.
DEA prohibitionists get knocked down a peg – read the latest on a hearing challenging a proposed ban of two psychedelic compounds.
We've got updates on two new psychedelic drugs that hope to treat binge eating and parkinson's respectively.
Psychedelics are on the ballot this November. Read how one veterans' group is using TV ads to advocate for legalization in Massachusetts.
PharmAla Biotech Holdings to partner with Harvard University hospital on new clinical trial.
The DEA calls for an increase in the manufacturing of the psychedelics ibogaine, psilocybin and psilocyn for research purposes.
The European Commission establishes citizens' initiative to promote psychedelic-assisted treatments.
Clinical Trials for a receptor agonist designed to treat adult patients with Absence Epilepsy as well as a Trial at Johns Hopkins Medicine for MDMA, plus developing research for Dementia
The DEA tried and failed to ban this psychedelic compound, and now the FDA has approved a study of its therapeutic effects.
Psilera, one our earliest portfolio companies, receives promising initial results from its in vivo preclinical studies.
New evidence supports psilocybin as a treatment for addiction and depression, and government agencies are taking notice.
Gilgamesh named one of Biotech's "Fierce 15"; FDA backpedals in a major win for psychedelic advocates.
Canada opens center for psychedelic therapy. Massachusetts scores a big win in their march towards legalization.
Wish you could buy psychedelics at your local drug store? In Jamaica, it's now possible thanks to Fontana Pharmacy and PATOO.
Could this biotech start-up jump start the ibogaine industry? And a student group rallies to oppose the DEA.
Could MDMA help abused dogs recover from PTSD? And new insights deepen our understanding of how psilocybin affects the brain.
Could Washington be the next state to legalize certain psychedelics for personal use? And how psychedelics can reprogram our neurons.
Interest in microdosing psychedelics surges amidst reforms. MA aims for a November ballot initiative after legislative stall. EEG marks 100 years shaping neuroscience.
The RAND Corporation released a new report on psychedelic regulation; University of Colorado opens a psychedelic research center; A study on extended-release ketamine tablets
Promising data from Mindbio; a bipartisan effort to provide psilocybin to military vets; American Medical Association favors decriminalization.
There are no FDA-approved pharmacotherapies to treat meth addiction, but Filament could be on the verge of changing that.
Federal health agency acknowledges the potential health benefits of psilocybin; Vermont could be on the path to decriminalizing shrooms.
Introducing New York City's next historic landmarks... psilocybin service centers?
Gilgamesh, a JLS portfolio company, secures a major deal with AbbVie Inc. to develop new therapeutics.
FDA to review a psychedelic drug application for the first time ever. Could our industry be on the verge of a historic milestone?
Morgan Stanley makes major play with Compass Pathways; perhaps the biggest validation yet of the psychedelic industry's economic potential.
Exciting updates on MDMA therapy for veterans and new PTSD treatments
Can California legislators overcome Newsom's veto? Plus atai Life Sciences publishes encouraging progress from Phase 1 study.
Our portfolio company, Psilera, makes waves in Tampa Bay with its dementia treatment.
Canadian health care provider to reimburse psychedelic therapies; Missouri to research ibogaine as a treatment for opioid addiction.
Massachusetts could legalize this November; Utah unanimously authorizes pilot program for MDMA treatment; update from atai Life Sciences.
Too many Americans are in prison for non-violent psychedelic drug offenses, but Maryland may have a plan to change that.
Could psychedelics reduce psychotic symptoms in teens? Plus Cybin, Inc. gets closer to first FDA approved psychedelic therapeutic for MDD.
MindBio Therapeutics, Atai Life Sciences, and MindMed provide updates on their historic clinical trials and drug studies.
Psychedelics industry bounces back with massive fundraising month, and now JP Morgan wants to get in on the action.
Avesta Ketamine and Wellness announces partnership with the Department of Veterans Affairs; Clearmind receives approval to begin new study.
FDA to consider MDMA-assisted therapy as a treatment for PTSD. Arizona takes first step towards legalizing psychedelic mushrooms.
Could psychedelics improve sexual health? Plus California legislators hope to win Governor Newsom's support with new legalization bill.
Could Psilera lead the fight against dementia? JLS is proud to update you on our portfolio company's innovative new drug.
Lawmakers speak openly about their psychedelic use. Plus the EU funds new psychedelic research and Cybin receives FDA clearance.
Could Gilgamesh soon have a ketamine drug ready for at home use? Plus the Ukraine military experiments with ibogaine.
Two major announcements from Atai Life Sciences; plus CPT codes for psychedelic-assisted therapy take effect.
MAPS submits application for first-ever FDA approved psychedelic-assisted therapy for PTSD; MindMed announces results for its drug MM-120.
Massachusetts activists pass huge milestone, forcing lawmakers to consider psychedelic legalization in 2024; and that's just the beginning!
Could this active warzone become a test bed for psychedelics? And SciSparc and Clearmind see positive results for obesity treatment program.
House hosts historic hearing on psychedelics; Massachusetts activists and governor push for legislation; Awkn Life Sciences update.
.png){kind=small}
